Ethical considerations in the regulation and use of herbal medicines in the European Union

被引:2
|
作者
Gatt, Anthony Raphael [1 ]
Bonanno, Patricia Vella [2 ,3 ]
Zammit, Raymond [1 ]
机构
[1] Univ Malta, Dept Moral Theol, Msida, Malta
[2] Univ Malta, Fac Hlth Sci, Dept Hlth Syst Management & Leadership, Msida, Malta
[3] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Scotland
来源
关键词
herbal medicines; traditional medicine; pharmaceutical regulation; access to healthcare products; pharmacovigilance; moral awareness; ALTERNATIVE MEDICINE; DIETARY-SUPPLEMENTS; CHINESE MEDICINE; COMPLEMENTARY; PHARMACOVIGILANCE; IDENTIFICATION; ORGANIZATIONS; FRAMEWORK; PRODUCTS; GINSENG;
D O I
10.3389/fmedt.2024.1358956
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The regulation and use of herbal medicines is a topic of debate due to concerns about their quality, safety, and efficacy. EU Directive 2004/24/EC on Herbal Medicinal Products was a significant step towards establishing a regulatory framework for herbal medicinal products in the EU, and bridging the gap between conventional and herbal medicines. This Directive allows herbal medicinal products to be marketed in the EU through full marketing authorisation, well-established use, and traditional use of herbal medicinal products. The framework relies on the correlation between the therapeutic claims of herbal medicine and the scientific evidence backing them up: the greater the claims made regarding medicinal benefits, the more evidence is required to substantiate its efficacy and safety. This regulatory framework acknowledges and incorporates traditional knowledge when evaluating herbal medicines, showcasing a balanced approach that values cultural traditions while mandating monographs for traditional herbal medicinal products. Excluding herbal medicines completely limits access to affordable treatment, particularly when they serve as the only alternative for some, and protects consumer autonomy. This EU framework could therefore serve as a practical guidance for the use and regulation of herbal medicines, even outside the EU. In conclusion, it is argued that the same moral imagination and courage shown by regulators in the case of herbal medicines could perhaps be used in the regulatory frameworks of other healthcare products.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Traditional herbal medicines in the European Union: Implementing standardization and regulation
    Knoess, Werner
    Chinou, Ioanna
    SCIENCE, 2015, 350 (6262) : S59 - S60
  • [2] Herbal medicines in European regulation
    Benzi, G
    Ceci, A
    PHARMACOLOGICAL RESEARCH, 1997, 35 (05) : 355 - 362
  • [3] Estimating the use of veterinary medicines in the European union
    Kools, Stefan A. E.
    Moltmann, Johann F.
    Knacker, Thomas
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2008, 50 (01) : 59 - 65
  • [4] Regulation of Herbal Medicines
    Knoess, Werner
    JOURNAL OF ETHNOPHARMACOLOGY, 2014, 158 : 448 - 448
  • [5] The European Regulation on medicines for paediatric use
    Dunne, Julia
    PAEDIATRIC RESPIRATORY REVIEWS, 2007, 8 (02) : 177 - 183
  • [6] Regulation of herbal medicines
    Rose, Les
    LANCET, 2011, 378 (9791): : 570 - 570
  • [7] The Legal and Regulatory Framework of Herbal Medicinal Products in the European Union: A Focus on the Traditional Herbal Medicines Category
    Anquez-Traxler, Christelle
    DRUG INFORMATION JOURNAL, 2011, 45 (01): : 15 - 23
  • [8] The Legal and Regulatory Framework of Herbal Medicinal Products in the European Union: A Focus on the Traditional Herbal Medicines Category
    Christelle Anquez-Traxler
    Drug information journal : DIJ / Drug Information Association, 2011, 45 : 15 - 23
  • [9] Orphan Medicines for Pediatric Use: A Focus on the European Union
    Bolislis, Winona Rei
    Corriol-Rohou, Solange
    Hill-Venning, Claire
    Hoogland, Hans
    Joos, Angelika
    King, David
    Kitcatt, Victoria
    Le Visage, Genevieve
    Kuhler, Thomas C.
    CLINICAL THERAPEUTICS, 2019, 41 (12) : 2630 - 2642
  • [10] The regulation of herbal medicines in Australia
    Briggs, DR
    TOXICOLOGY, 2001, 164 (1-3) : 39 - 39